Efficacy of LCQ908 on Cardiovascular Risk

Status:
Terminated

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.

Phase 2

Novartis Pharmaceuticals